1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Neurogenetic Testing Market, By Type
5.1 Introduction
5.2 Microarray Analysis
5.3 Whole-Exome Sequencing (WES)
5.4 Multiplex Ligation Dependent Probe Amplification (MLPA)
5.5 Polymerase Chain Reaction (PCR) Tests
5.6 Other Types
6 Global Neurogenetic Testing Market, By End User
6.1 Introduction
6.2 Hospitals
6.3 Specialty Clinics
6.4 Research Institutes
6.5 Diagnostics Laboratories
6.6 Other End Users
7 Global Neurogenetic Testing Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa
8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiling
9.1 Invitae Corporation
9.2 Ambry Genetics
9.3 PerkinElmer
9.4 GeneDx
9.5 Centogene
9.6 Blueprint Genetics
9.7 Genomic Health (Exact Sciences)
9.8 Fulgent Genetics
9.9 QIAGEN
9.10 Baylor Genetics
List of Tables
Table 1 Global Neurogenetic Testing Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 3 Global Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 4 Global Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 5 Global Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 6 Global Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 7 Global Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 8 Global Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 9 Global Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 10 Global Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 11 Global Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 12 Global Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 13 Global Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 14 North America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
Table 15 North America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 16 North America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 17 North America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 18 North America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 19 North America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 20 North America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 21 North America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 22 North America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 23 North America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 24 North America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 25 North America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 26 North America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 27 Europe Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
Table 28 Europe Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 29 Europe Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 30 Europe Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 31 Europe Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 32 Europe Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 33 Europe Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 34 Europe Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 35 Europe Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 36 Europe Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 37 Europe Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 38 Europe Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 39 Europe Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 40 Asia Pacific Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
Table 41 Asia Pacific Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 42 Asia Pacific Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 43 Asia Pacific Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 44 Asia Pacific Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 45 Asia Pacific Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 46 Asia Pacific Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 47 Asia Pacific Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 48 Asia Pacific Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 49 Asia Pacific Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 50 Asia Pacific Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 51 Asia Pacific Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 52 Asia Pacific Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 53 South America Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
Table 54 South America Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 55 South America Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 56 South America Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 57 South America Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 58 South America Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 59 South America Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 60 South America Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 61 South America Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 62 South America Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 63 South America Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 64 South America Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 65 South America Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
Table 66 Middle East & Africa Neurogenetic Testing Market Outlook, By Country (2021-2030) ($MN)
Table 67 Middle East & Africa Neurogenetic Testing Market Outlook, By Type (2021-2030) ($MN)
Table 68 Middle East & Africa Neurogenetic Testing Market Outlook, By Microarray Analysis (2021-2030) ($MN)
Table 69 Middle East & Africa Neurogenetic Testing Market Outlook, By Whole-Exome Sequencing (WES) (2021-2030) ($MN)
Table 70 Middle East & Africa Neurogenetic Testing Market Outlook, By Multiplex Ligation Dependent Probe Amplification (MLPA) (2021-2030) ($MN)
Table 71 Middle East & Africa Neurogenetic Testing Market Outlook, By Polymerase Chain Reaction (PCR) Tests (2021-2030) ($MN)
Table 72 Middle East & Africa Neurogenetic Testing Market Outlook, By Other Types (2021-2030) ($MN)
Table 73 Middle East & Africa Neurogenetic Testing Market Outlook, By End User (2021-2030) ($MN)
Table 74 Middle East & Africa Neurogenetic Testing Market Outlook, By Hospitals (2021-2030) ($MN)
Table 75 Middle East & Africa Neurogenetic Testing Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 76 Middle East & Africa Neurogenetic Testing Market Outlook, By Research Institutes (2021-2030) ($MN)
Table 77 Middle East & Africa Neurogenetic Testing Market Outlook, By Diagnostics Laboratories (2021-2030) ($MN)
Table 78 Middle East & Africa Neurogenetic Testing Market Outlook, By Other End Users (2021-2030) ($MN)
| ※参考情報 神経遺伝学的検査とは、神経系に関連する遺伝的要因を調査するための検査です。この検査は主に、神経を含む疾患の診断やリスク評価、治療法の選択、家族計画において重要な役割を果たします。近年、この分野は急速に発展しており、様々な疾患に対する理解が深まっています。 神経遺伝学的検査の種類としては、主にDNAシーケンシング、特定の遺伝子の変異解析、マイクロアレイ解析、エピジェネティクス解析などがあります。DNAシーケンシングは、特定の遺伝子やゲノム全体の配列を決定する方法で、特定の疾患に関連する遺伝子の変異を明らかにするために用いられます。変異解析では、既知の遺伝子変異を確認することで、特定の神経疾患が存在するかどうかを判断します。 神経遺伝学的検査の用途は非常に多岐にわたります。例えば、遺伝性神経疾患の診断はその一つです。ハンチントン病や筋萎縮性側索硬化症（ALS）など、特定の遺伝子変異が関与している疾患が多く、これらを早期に発見することにより、適切な治療法を選択する手助けになります。また、神経発達障害や自己免疫疾患においても、遺伝子的なリスクを評価する目的で使用されることがあります。 臨床的には、神経遺伝学的検査は、特に遺伝子によるリスク評価ができることから、医師が患者に対して正確な情報を提供し、治療方針を立てるための参考となります。家族内に疾患がある場合、どのような対策を講じるべきかを知る手段としても非常に有効です。加えて、遺伝カウンセリングと併用することで、得られた情報を基にしたより効果的なコミュニケーションが可能になります。 関連技術としては、次世代シーケンシング技術（NGS）が挙げられます。これは、従来のシーケンシングよりも高速かつ低コストで大量の遺伝情報を取得できる技術です。神経疾患に関連する遺伝子の変異を広範囲にわたり検査することができ、より多くの情報を得ることが可能になります。また、バイオインフォマティクス技術も重要で、得られたデータの解析や解釈に寄与します。 さらに、エピジェネティクスの研究も進行中であり、遺伝子発現を調節するメカニズムを理解することは神経疾患の研究において重要な側面です。環境因子が遺伝子の機能に与える影響を明らかにすることで、疾患の予防策や治療法の開発に新しい視点を提供することが期待されています。 また、神経遺伝学的検査の倫理的な側面も重要です。遺伝情報がもたらすプライバシーや保険、雇用に関連する問題があるため、適切な情報の取り扱いや同意手続きが求められます。患者や家族が結果をどう受け止め、どのように活用していくかは、慎重に考慮する必要があります。 このように、神経遺伝学的検査は神経疾患の理解や治療において欠かせない重要な手段であり、今後も技術の進展と共にさらなる発展が期待されます。疾患の早期発見や個別化医療の実現に寄与することが、患者の生活の質を向上させる一助となることでしょう。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
